We conducted a retrospective registry-based analysis to compare the outcome of 361 allogeneic human leukocyte antigen (HLA)-identical peripheral blood stem cell transplants (PBSCT) with reduced intensity conditioning (RIC) to that of 1369 autologous (auto) PBSCT in patients aged 50 years or older with de novo acute myeloid leukemia (AML), performed from 1997 until 2003 and reported to the European Group for Blood and Marrow Transplantation. Median age was 58 and 57 years in the RIC and auto groups, respectively. RIC patients had more advanced disease at the time of transplant. At a median follow-up of 24 months for RIC and 16 months for auto, multivariate analysis showed a lower risk for relapse (RR 0.77, P ¼ 0.013) without increased non-relapse mortality (NRM) in RIC patients (RR 1.26, P ¼ 0.28). Moreover, leukemia-free survival (RR 1.22, P ¼ 0.02) and overall survival (OS) (RR 1.32, P ¼ 0.005) were superior in the RIC group. In patients in 1st (CR), fewer relapses were counterbalanced by significantly increased NRM. Therefore, there was no survival advantage in this subgroup. In patients in 2nd or subsequent CR, LFS and OS were superior in the RIC group. RIC transplants show encouraging results in this older patient population with de novo AML.
Introduction
Acute myeloid leukemia (AML) mainly affects old adults with a median age at diagnosis of 65 years and with very poor outcomes compared to those of younger patients, mainly due to more aggressive disease biology and more treatment-related complications. 1 Moreover, in this population, therapeutic options are limited and the choice of consolidation treatment depends on several factors including patient's performance status and prognosis, donor availability, expected treatment toxicity, long-term complications and attitude of the treating team. [2] [3] [4] Autologous stem cell transplantation (auto) is used as consolidation treatment of AML for selected patients in first complete remission (CR), or as salvage-treatment for patients in second CR or more advanced disease. It allows intensification of the antitumor effect by the administration of high doses of chemotherapy and offers the advantage of the availability of an autologous graft for most patients. The main concern with this transplant modality is the high rate of relapse probably due to the lack of a graft-versus-leukemia (GvL) effect 5, 6 and the possible graft contamination by tumor cells. 5 On the other hand, allogeneic myeloablative transplantation offers the advantage of a potential GvL effect. Indeed, prospective randomized trials [7] [8] [9] [10] comparing the two transplant modalities favor the allogeneic transplant modality in terms of better leukemia-free survival (LFS) and decreased relapse incidence. However, transplant-related mortality (TRM) is significantly higher in the allogeneic setting and increases with age. 11 Other downsides of conventional myeloablative allogeneic transplantation are that it is restricted to patients with a good performance status, without co-morbidities and, of course, to those patients having a compatible donor.
Reduced-intensity conditioning (RIC) regimens within the allogeneic setting 12 aim to reduce non-relapse mortality (NRM) without loss of the antitumor activity, relying solely on the GvL effect. [13] [14] [15] This type of procedure, with the use of related or unrelated donor grafts, can thus be applied to an older patient population, otherwise ineligible for conventional allogeneic transplantation. [16] [17] [18] [19] [20] [21] [22] Indeed, two recent retrospective studies comparing the outcomes of RIC versus myeloablative allogeneic transplants for patients older than 50 years showed significantly lower non-relapse mortalities in the RIC groups, although LFS was the same in both groups due to higher relapse rates in the RIC groups in both studies. 23, 24 RIC allogeneic stem cell transplants have thus become an increasingly used treatment alternative to autologous transplants in older adults. To our knowledge, there exists no comparison of outcomes between autologous and RIC allogeneic transplants in older patients with AML. We therefore conducted a retrospective risk-adjusted comparative analysis of these two transplant modalities focusing on early transplant outcomes.
Transplants were performed from 1997 to 2003 and reported to the European Group for Blood and Marrow Transplantation registry (EBMT).
Materials and methods

Data collection
EBMT registry database was used to collect the data on allogeneic RIC and auto transplants. This registry includes data from more than 450 transplantation centers which are required to file an annual report of all consecutive stem cell transplants with follow-ups made by EBMT physicians. The database was checked to verify compliance and detect overlapping reports.
Inclusion criteria
This study evaluated outcomes of adult patients aged 50 years or older with de novo AML, except acute promyelocytic leukemia, who underwent either familial human leukocyte antigen (HLA)-identical allogeneic RIC peripheral blood stem cell transplants (PBSCT) or auto PBSCT from 1997 to 2003 inclusively, and for whom there were adequate data on outcomes. The conditioning regimen was considered of reduced intensity if labeled as such in the database and later confirmed by additional questionnaire to the treating center, the dose of total body irradiation (TBI) if applicable did not exceed 4 Grays and/or non-myeloablative doses of chemotherapy were used (Busulfan total dose p8 mg/kg). A total of 361 allogeneic RIC and 1369 auto-transplant patients met the inclusion criteria.
Conditioning regimens and cell dose
The majority (93%) of RIC patients received a fludarabine-based conditioning regimen. Low-dose TBI was administered to 26% of patients. Out of 25 different conditioning regimens used, the most commonly used ones were: Fludarabine þ Busulfan (42%), Fludarabine þ TBI 2 Gy (22%), Fludarabine þ Melphalan (16%), Fludarabine þ Cyclophosphamide (7%) and other regimens in 13%. The mean doses of commonly used chemotherapy drugs were: Fludarabine 135 mg/m 2 , Busulfan 6 mg/kg and Melphalan 140 mg/m 2 . In the auto group, the majority of patients received a busulfan-based conditioning regimen and only 15% of patients received a TBI-based conditioning regimen. RIC patients received a median of 9.7 Â 10 6 /kg (range, 1.3-42.5 Â 10 6 /kg) nucleated cells, whereas auto patients received 6.73 Â 10 6 /kg (range, 0.1-1.77 Â 10 6 /kg) nucleated cells (Po0.0001).
GvHD prevention in the RIC group
In the RIC group, 34% patients received anti-T-cell serotherapy (anti-thymocyte, anti-lymphocyte globulin or other monoclonal antibody) as part of the conditioning regimen and 3% of patients received an in vitro T-cell depleted graft. Graft-versus-host disease (GvHD) prophylaxis regimen was based on cyclosporine A (CSA) in the majority of patients (96%), associated or not to other drugs: CSA alone in 46%, CSA þ methotrexate in 40% or CSA þ mycophenolate mofetil in 9% of patients.
End points
The EBMT (Med-B form) definitions for clinical end points were used. Neutrophil engraftment was defined as the achievement of a neutrophil count of at least 500 per cubic millimeter for 2 consecutive days. Primary graft failure was defined as the absence of neutrophil engraftment. Graft loss was defined as the decrease of neutrophils to a low level after initial engraftment took place. In the RIC group, acute GvHD was diagnosed and graded according to published criteria 25 and patients were evaluated one day or more after transplantation. Chronic GvHD was defined according to published criteria. 26 NRM was defined as death related to transplantation and not to relapse. Relapse was defined on the basis of morphologic evidence of leukemia in bone marrow or other sites. Overall survival (OS) was calculated from transplantation to death from any cause, and LFS was defined as the time from transplantation to either first relapse or death in CR. NRM, relapse, OS and LFS were evaluated at 2 years as this corresponded to the median followup of the patients. Follow-up was calculated from the day of transplantation considering only patients alive.
Statistical analysis
Patient-, disease-and transplant-related variables of both groups were compared, using the w 2 statistic for categorical and the Mann-Whitney test for continuous variables. Variables considered were recipient age and sex; disease characteristics (FAB classification, cytogenetics, white blood count at time of diagnosis, donor characteristics (age, sex), disease status at transplant (1st CR, 2nd or subsequent CR and advanced disease)), transplant characteristics including year of transplant, GvHD prophylaxis. In order to treat missing values for cytogenetics, we first looked at the outcomes according to the four cytogenetics risk groups (good, intermediate, poor and missing). We found that the 2-year outcomes of the missing data group were similar to those of the intermediate cytogenetics group. Therefore, these two groups were merged for the multivariate analyses. Factors differing in distribution between the two groups with a Po0.10 and factors known to influence outcomes (such as status at transplant) were included in the final models.
Cumulative incidence curves were used in a competing risks setting. Disease-unrelated death was treated as a competing event to calculate the probability of relapse. Relapse and death from any cause were treated as competing events for chronic GvHD. Relapse and disease-related death were treated as competing events for NRM. 27 Probabilities of survival and LFS were calculated using the Kaplan-Meier estimate; the log-rank test was used for univariate comparisons. Associations of graft type with outcomes were evaluated in multivariate analyses, using Cox proportional hazards for LFS and survival, 28 and proportional sub-distribution hazard regression model of Fine and Gray for other outcomes. 29 All P-values are two-sided with type I error rate fixed at 0.05. Statistical analyses were performed with SPSS (Inc., Chicago, IL, USA) and Splus (MathSoft, Inc. Seattle, USA) software packages. Table 1 shows the characteristics of the patients aged 50 years or older who underwent RIC or auto-transplants for AML. In terms of patient characteristics, age was similar in both groups but there were more men in the RIC group (P ¼ 0.001). This difference did not have a prognostic impact as the multivariate analysis showed similar outcomes for the two genders (data not shown). For disease characteristics, there was no difference in terms of French-American-British category, namely there was no more M5, M6 or M7 leukemias in one group compared to the other. However, RIC recipients had more advanced disease at the time of transplantation and they were transplanted later from diagnosis compared to auto recipients (Po0.0001). This latter difference was linked to the difference in terms of disease status at transplant and did not remain significant when studying the three subgroups separately. Finally, RIC transplants were performed in more recent years compared to autologous transplants (Po0.0001); however, the year of transplant did not influence outcomes in the multivariate analysis (data not shown). The proportion of unknown cytogenetics was higher among autografted patients; nonetheless, considering available data, more RIC patients compared to auto patients had poor cytogenetics (Po0.0001).
Results
Patients and transplantation characteristics
Engraftment and hematopoietic chimerism
Neutrophil engraftment (4500/mm 3 ) was significantly delayed in the RIC group compared to the auto group. The median time required for achievement of neutrophil engraftment was 16 days (range, 0-50) in the RIC group compared to 12 days (range, 3-378) in the auto group (Po0.0001). Primary graft failure occurred in nine patients (3%) in the RIC group and in 31 (2.3%) patients in the auto group. Three patients in the RIC group and four patients in the auto group subsequently lost their grafts.
Chimerism analyses were available for 195 of the 361 patients in the RIC group. They showed that 108 patients (59%) reached full donor chimerism, 71 patients (39%) had mixed chimerism and three patients (2%) had autologous reconstitution within 100 days after transplant.
Acute and chronic GvHD in RIC patients
Acute GvHD developed in 129 patients (38%), with 74 patients (22%) having grades II-IV acute GvHD and 30 patients (9%) having severe grade III-IV acute GvHD.
Data on chronic GvHD was available for 254 patients out of 306 at risk. Of those, 126 (50%) developed chronic GvHD with a cumulative incidence at 2 years of 4973%. Chronic GvHD was extensive in 54 patients (46%).
Survival
Median follow-up was 24 months (range, 1-73 months) for RIC patients and 16 months (range, 0.5-94 months) for auto patients. Unadjusted 2-year probabilities of OS, LFS, relapse incidence and NRM are shown in Table 2 . At 2 years, unadjusted LFS was 42% in the RIC group and 39% in the auto group (P ¼ 0.99; Figure 1 ). Two-year OS was 54% in the RIC group compared to 50% in the auto group (P ¼ 0.86). Unadjusted probabilities of LFS and OS were globally not statistically different between the two transplant groups, as for the subgroups of patients in 1st CR and with advanced disease. However, after adjustment for patient-, disease-and transplant-related variables in the multivariate analysis, LFS and OS are superior in the RIC group (Table 3) . Of note, there was a statistically significant difference in unadjusted probabilities of OS and LFS following RIC transplants for the subgroup of patients in 2nd or subsequent CR.
Relapse
Although unadjusted 2-year probabilities of relapse were not statistically different in both groups (Figure 2) , multivariate analysis demonstrated a statistically significant difference in relapse, with less relapse in the RIC group compared to the auto group (relative risk 0.77, 95% CI 0.63-0.95, P ¼ 0.013; Table 3 ).
Non relapse mortality
Unadjusted 1-year probabilities of NRM are shown in Table 2 . Multivariate analysis did not show any statistically significant Table 1 Characteristics of patients 50 years and older receiving allogeneic reduced intensity conditioning or autologous transplants for acute myeloid leukemia difference in NRM between the two transplant groups (Table 3 and Figure 3 ). Of note, in the subgroup of patients in 1st CR, RIC patients had significantly higher unadjusted 2-year probability of NRM than auto transplant recipients.
Causes of death
Death occurred in 167 of 361 (46%) RIC recipients and 618 of 1369 (45%) auto recipients. The main causes of death in the RIC group were: relapse (104 patients, 65%), GVHD (29 patients, 18%), infections (15 patients, 9%), interstitial pneumonitis (three patients, 2%), hemorrhage (three patients, 2%), secondary malignancy (one patient) and other causes (five patients). The main causes of death in the auto group were relapse (478 patients, 82%), infections (64 patients, 11%), interstitial pneumonitis (nine patients), hemorrhage (six patients), cardiac toxicity (four patients), secondary malignancy (four patients), graft failure (two patients) and other causes (14 patients). 
Discussion
In this study, older patients with AML undergoing RIC allogeneic transplants had a lower risk of relapse, better LFS and OS without an increased risk of NRM, compared to a group of patients receiving autologous transplants. These conclusions are based from a retrospective comparison performed within a registry database, based on a large number of patients, with multivariate analysis adjusted for patient-, disease-and transplant-related differences.
In a subgroup analysis according to the status of the disease at transplant, we observed that patients undergoing RIC allogeneic transplants in first CR had a statistically significant lower cumulative incidence of relapse compared to patients receiving an autologous transplant. In this subgroup, this did not translate in a survival advantage because of the NRM observed. The lower relapse incidence may be explained by the presence of a GvL effect acting best when the disease burden at time of transplant is minimal. In fact, previous prospective studies comparing autologous with allogeneic transplantation in young patients in first CR had also found that relapse is decreased, and therefore disease-free survival is higher after allogeneic transplantation. 7, 9, 10 We also found a lower unadjusted cumulative incidence of relapse in the subgroup of patients in second CR; however, this observation was not statistically significant. In the subgroup of patients in advanced phase of disease at time of transplant, the relapse rate was very high (460%) with either transplant modality. A recent study also demonstrated the poor outcomes of patients with active disease at time of transplant, whether they received a RIC or a myeloablative transplant. 21 Cytogenetics probably have a prognostic impact in our study since, as expected, we observe better survival in patients with good cytogenetics and worse survival in patients with poor cytogenetics in the multivariate analysis, independently of the type of transplant received.
Overall, there is no difference in NRM between the two transplant groups. However, there is a significant difference for this outcome in patients in first CR in the univariate analysis, with 17% in RIC allogeneic transplant group compared to 8% in the autologous transplant group. The main causes of transplantrelated deaths in the allogeneic RIC allogeneic transplant group were graft-versus-host disease and infections, accounting for 27% of the total number of deaths. There were similar proportions of toxic deaths in either transplant group. A reduction in mortality due to GvHD in the RIC setting by optimal use of immunosuppression is an active domain of current clinical research. For example, in order to decrease the rate of GvHD, some groups have shown interesting results using alemtuzumab (Campath) in the reduced intensity allogeneic transplant setting. 30 Leukemia-free and OS were superior in the allogeneic setting in the multivariate analysis. Indeed, we observed median survivals of 29 months in the allogeneic and 24 months in the autologous transplant settings. Of note, in the subgroup of patients in second or subsequent CR, the unadjusted 2-year probabilities of OS and LFS were superior following RIC allogeneic transplants.
Subgroup analysis in the present study was limited by the small number of patients in the subgroups of patients in 2nd or subsequent CR and with advanced disease. Follow-up in studies including RIC allogeneic transplants is limited due to the wide implantation of this new transplant technique in our transplant centers only in recent years. Few cytogenetics data are reported in the EBMT database; therefore, we were not able to evaluate their impact in more detail, particularly in the different subgroups of patients based on disease status at transplant. Reasons for performing an allogeneic reduced intensity transplant versus an autologous transplant as well as the presence of co-morbidities are not part of the required report to the EBMT database. In order to circumvent this aspect, we have selected patients older than 50 years since this cutoff is used by many transplant centers for not performing a myeloablative allogeneic transplant. A bias inherent to all comparative transplant studies is the selection of patients given a transplant. Indeed, in the autologous setting, difficulties in the autograft harvest process may arise, rendering it impossible to perform an autologous transplant in a particular patient. As well, given that only 30% of patients will have an HLA-identical donor and that donor age is a limiting factor for donation, only a minority of patients will be candidates for an HLA-identical transplant. However, recent studies have shown that HLA-identical RIC transplants give similar results to HLA-matched unrelated transplants. [20] [21] [22] It is therefore likely that patients included in the present study were highly selected for best initial response to induction and consolidation therapy, and that those patients who relapsed early during consolidation or while waiting for transplantation may have been excluded from the present analysis. Only prospective studies starting at leukemia diagnosis or time of first CR will allow drawing definitive conclusions on the place of different consolidation strategies for this high-risk population. However, due to very poor long-term results with chemotherapy alone (disease-free survival around 5-15%), 1 new treatment strategies such as reduced intensity allogeneic transplants must be included in the current practice but prospectively analyzed.
In summary, this retrospective registry-based study demonstrates superior outcomes after allogeneic RIC transplants compared to autologous transplants in older patients with AML. NRM remains an obstacle in the allogeneic setting, particularly in the subgroup of patients in first CR who otherwise have less risk of relapse. Nevertheless, these data are encouraging for the continued use of allogeneic RIC transplants in this population of older patients. Better selection of patients based on disease status, cytogenetics risk group, co-morbid conditions as well as the choice of the conditioning regimen may allow reduction of the NRM with reduced intensity allogeneic transplants in the future. The role of each transplant modality in different subsets of patients should be defined in prospective comparative studies.
